WASHINGTON, D.C. – In partnership with the Centers for Disease Control and Prevention (CDC) through the Antimicrobial Resistance (AMR) Challenge, AdvaMedDx® and several AdvaMedDx® member companies made public commitments to bolster efforts to combat the global prevalence of AMR. The CDC will be accepting commitments over the course of the next year.

“AdvaMedDx® member companies work hard every day to discover, develop and deliver innovative diagnostic solutions for early detection and surveillance of resistant germs,” said Susan Van Meter, Executive Director of AdvaMedDx®. “We are proud to showcase their achievements and we are dedicated to ensuring the global policy landscape supports their efforts. In the fight against AMR, everyone has a part to play, and the diagnostics community looks forward to helping drive progress through the CDC’s AMR Challenge.”   

In its AMR Challenge commitment, AdvaMedDx® promised to advocate for policies that incentivize and support robust antibiotic stewardship programs informed by diagnostic data; educate provider and professional organizations to encourage the appropriate use of diagnostics in antibiotic stewardship programs; and raise awareness of AMR for domestic and international lawmakers and other relevant stakeholders.

AdvaMedDx® member companies also making early AMR Challenge commitments include BD, bioMérieux, Cepheid and Roche Diagnostics.

The AMR Challenge is a multi-year initiative spearheaded by the CDC to encourage cross-sector collaboration to address the threat of AMR to public health. The Challenge focuses on five commitment areas: tracking and data; infection prevention and control; antibiotic use; environment and sanitation; and vaccines, therapeutics, and diagnostics.

View more information about AdvaMedDx®’s commitment and the AMR Challenge here.

###

Press Contact:

Elyse Petroni
[email protected]
202-434-7271